News

During the American Society of Clinical Oncology 2020 Annual Meeting, Flatiron Health, Foundation Medicine, and Genentech will be presenting plans for the Prospective Clinico-Genomic study (PCG), a low-interventional pilot that will use a technology-enabled prospective data collection platform to simplify data collection for patients with lung cancer being treated through clinical trials. The idea is collect blood samples using Foundation Medicine’s liquid biopsy assay and analyze the results through Flatiron’s platform, to see if genomic changes can be detected over the course of cancer treatment. Bobby Green, MD, chief medical officer for Flatiron Health, spoke with Managed Healthcare Executive®.

The 2020 annual meeting of the American Society of Clinical Oncology that launches today will feature the first results from CITYSCAPE, a trial involving a novel immunotherapy approach in non-small cell lung cancer (NSCLC). This phase 2 trial is the first to combine the immunotherapy tiragolumab with atelzolizumab (Tecentriq), the monoclonal antibody that targets the programmed cell death ligand-1 (PD-L1).

It’s difficult for people seeking mental health treatment to get it right now. COVID-19 has effectively halted most non-essential doctors’ visits and accessing behavioral health treatment is even more challenging than in the past due to limitations with residential treatment and outpatient group sessions.

In today’s COVID-19 environment, care management has become more important than ever. Currently, about one in four Americans live with multiple chronic conditions, and when one considers that 80% of outcomes are determined by nonclinical factors, it’s an indisputable claim that people need help between healthcare encounters.

As the coronavirus pandemic swept the U.S., state governments mandated dental offices open only for emergency procedures. But in the coming weeks, some dental practices may resume regular appointments in individual states where businesses considered “essential” are allowed to re-open.